Synopsis
Synopsis
0
VMF
0
Australia
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Centedrin
2. Concerta
3. Daytrana
4. Equasym
5. Hydrochloride, Methylphenidate
6. Metadate
7. Methylin
8. Methylphenidate
9. Phenidylate
10. Ritalin
11. Ritalin Sr
12. Ritalin-sr
13. Ritaline
14. Tsentedrin
1. 298-59-9
2. Centedrin
3. Centedrine
4. Methylphenidate Hcl
5. Concerta
6. Ritalin
7. Methylphenidate.hcl
8. Metadate
9. Methylin
10. Metilfenidat Hydrochloride
11. Ritalin Sr
12. H-tic-otbu.hcl
13. Threo-methylphenidate Hydrochloride
14. Daytrana
15. Methylin Er
16. Methylphenidylacetate Hydrochloride
17. Ritalin La
18. Methylphenidate (hydrochloride)
19. Ritalin Hydrochloride
20. Ritalin-sr
21. Methyl 2-phenyl-2-piperidin-2-ylacetate;hydrochloride
22. Nsc-169868
23. Ncgc00091942-01
24. Rilaline
25. Dsstox_cid_886
26. Dsstox_rid_75843
27. Dsstox_gsid_20886
28. Methyl Phenyl(piperidin-2-yl)acetate Hydrochloride
29. Quillichew
30. Quillivant
31. Aptensio
32. Foquest
33. Meridil Hydrochloride
34. Oros Mph
35. Aptensio Xr
36. Rilatine
37. Quillivant Xr
38. Quillichew Er
39. Chebi:31836
40. Cas-298-59-9
41. Nsc 169868
42. Ccris 6258
43. Methyl 2-phenyl-2-(piperidin-2-yl)acetate Hydrochloride
44. Einecs 206-065-3
45. Spd544
46. Spd-544
47. Methylphenidate Hydrochloride Er
48. Concerta (tn)
49. Metadate (tn)
50. Methyl Phenidate Hcl
51. Ritalin (tn)
52. Methyl Alpha-phenyl-2-piperidineacetate Hydrochloride
53. Quillivant Xr (tn)
54. Methylphenidate Hydrochloride [usp:jan]
55. Methylphenidate(ritalin)
56. Methyl .alpha.-phenyl-2-piperidineacetate Hydrochloride
57. Chembl1722
58. Schembl41067
59. Mls003922100
60. Dtxsid8020886
61. Methylphenidate Hydrochloride Cii
62. Hy-b1091a
63. Pharmakon1600-01505907
64. Bcp34044
65. Tox21_111186
66. Tox21_200309
67. 2-piperidineacetic Acid, Alpha-phenyl-, Methyl Ester, Hydrochloride
68. Mfcd00058191
69. Nsc169868
70. Nsc759278
71. Akos016010356
72. Ccg-213572
73. Cs-4658
74. Nsc-759278
75. Sb13180
76. Wln: T6mtj Byr & Vo1 & Gh
77. 2-piperidineacetic Acid, Alpha-phenyl-, Methyl Ester, Hydrochloride, (r*,r*)-(+-)-
78. Methylphenidate Hydrochloride (jan/usp)
79. Ncgc00257863-01
80. Smr000058998
81. Ft-0672045
82. Ft-0672046
83. Ft-0672048
84. Ft-0672050
85. D01296
86. 298m599
87. 2-piperidineacetic Acid, Methyl Ester, Hydrochloride
88. Methylphenidate Hydrochloride(ritalin Hydrochloride)
89. Methylphenidate Hcl;threo-methylphenidate Hydrochloride
90. Q26840773
91. Methyl 2-phenyl-2-(piperidin-2-yl)acetate Hcl
92. Methylphenidate Hydrochloride, European Pharmacopoeia (ep) Reference Standard
93. Methylphenidate Hydrochloride Solution, (racemic Mixture), Ampule Of 1 Ml, 1.0 Mg/ml In Methanol (as Free Base), Certified Reference Material
Molecular Weight | 269.77 g/mol |
---|---|
Molecular Formula | C14H20ClNO2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 3 |
Rotatable Bond Count | 4 |
Exact Mass | 269.1182566 g/mol |
Monoisotopic Mass | 269.1182566 g/mol |
Topological Polar Surface Area | 38.3 Ų |
Heavy Atom Count | 18 |
Formal Charge | 0 |
Complexity | 249 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 2 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 16 | |
---|---|
Drug Name | Concerta |
PubMed Health | Methylphenidate |
Drug Classes | CNS Stimulant, Central Nervous System Agent |
Drug Label | CONCERTA is a central nervous system (CNS) stimulant. CONCERTA is available in four tablet strengths. Each extended-release tablet for once-a-day oral administration contains 18, 27, 36, or 54 mg of methylphenidate HCl USP and is designed to have... |
Active Ingredient | Methylphenidate hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | 54mg; 18mg; 27mg; 36mg |
Market Status | Prescription |
Company | Janssen Pharms |
2 of 16 | |
---|---|
Drug Name | Metadate cd |
PubMed Health | Methylphenidate |
Drug Classes | CNS Stimulant, Central Nervous System Agent |
Drug Label | METADATE CD is a central nervous system (CNS) stimulant. The extended-release capsules comprise both immediate-release (IR) and extended-release (ER) beads such that 30% of the dose is provided by the IR component and 70% of the dose is provided by t... |
Active Ingredient | Methylphenidate hydrochloride |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | 30mg; 50mg; 60mg; 10mg; 40mg; 20mg |
Market Status | Prescription |
Company | Ucb |
3 of 16 | |
---|---|
Drug Name | Metadate er |
PubMed Health | Methylphenidate (By mouth) |
Drug Classes | CNS Stimulant, Central Nervous System Agent |
Drug Label | METADATE ER Tablets (methylphenidate hydrochloride extended-release tablets, USP) are a mild central nervous system (CNS) stimulant. METADATE ER is available as 20 mg extended-release tablets for oral administration.Methylphenidate hydrochloride is m... |
Active Ingredient | Methylphenidate hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | 20mg |
Market Status | Prescription |
Company | Ucb |
4 of 16 | |
---|---|
Drug Name | Methylin er |
PubMed Health | Methylphenidate |
Drug Classes | CNS Stimulant, Central Nervous System Agent |
Drug Label | Methylphenidate hydrochloride is a mild central nervous system (CNS) stimulant, available for oral administration as tablets of 5 mg, 10 mg, and 20 mg and as extended-release tablets of 10 mg and 20 mg. Methylphenidate hydrochloride is methyl -phen... |
Active Ingredient | Methylphenidate hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | 10mg; 20mg |
Market Status | Prescription |
Company | Mallinckrodt |
5 of 16 | |
---|---|
Drug Name | Methylphenidate hydrochloride |
Drug Label | Methylphenidate hydrochloride is a mild central nervous system (CNS) stimulant, available for oral administration as tablets of 5 mg, 10 mg, and 20 mg and as extended-release tablets of 10 mg and 20 mg. Methylphenidate hydrochloride is methyl -phen... |
Active Ingredient | Methylphenidate hydrochloride |
Dosage Form | Tablet, extended release; Tablet; Capsule, extended release; Solution |
Route | oral; Oral |
Strength | 10mg/5ml; 18mg; 30mg; 27mg; 36mg; 5mg; 54mg; 50mg; 60mg; 10mg; 5mg/5ml; 40mg; 20mg |
Market Status | Tentative Approval; Prescription |
Company | Corepharma; Vintage Pharms; Actavis Labs Fl; Sun Pharm Inds; Barr Labs; Mallinckrodt; Watson Labs; Actavis S Atlantic; Teva Pharms; Caraco; Ucb; Kudco Ireland; Tris Pharma |
6 of 16 | |
---|---|
Drug Name | Quillivant xr |
Drug Label | QUILLIVANT XR is a powder that, after reconstitution with water, forms an extended-release oral suspension formulation of methylphenidate intended for once daily oral administration. QUILLIVANT XR contains approximately 20% immediate-release and 80%... |
Active Ingredient | Methylphenidate hydrochloride |
Dosage Form | For suspension, extended release |
Route | Oral |
Strength | 5mg/ml |
Market Status | Prescription |
Company | Nextwave Pharms |
7 of 16 | |
---|---|
Drug Name | Ritalin |
Drug Label | Ritalin hydrochloride, methylphenidate hydrochloride USP, is a mild central nervous system (CNS) stimulant, available as tablets of 5, 10, and 20 mg for oral administration; Ritalin-SR is available as sustained-release tablets of 20 mg for oral admin... |
Active Ingredient | Methylphenidate hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 5mg; 10mg; 20mg |
Market Status | Prescription |
Company | Novartis |
8 of 16 | |
---|---|
Drug Name | Ritalin la |
Drug Label | Methylphenidate hydrochloride is a central nervous system (CNS) stimulant. Ritalin LA (methylphenidate hydrochloride) extended-release capsules is an extended-release formulation of methylphenidate with a bi-modal release profile. Ritalin LA uses t... |
Active Ingredient | Methylphenidate hydrochloride |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | 30mg; 10mg; 40mg; 20mg |
Market Status | Prescription |
Company | Novartis |
9 of 16 | |
---|---|
Drug Name | Concerta |
PubMed Health | Methylphenidate |
Drug Classes | CNS Stimulant, Central Nervous System Agent |
Drug Label | CONCERTA is a central nervous system (CNS) stimulant. CONCERTA is available in four tablet strengths. Each extended-release tablet for once-a-day oral administration contains 18, 27, 36, or 54 mg of methylphenidate HCl USP and is designed to have... |
Active Ingredient | Methylphenidate hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | 54mg; 18mg; 27mg; 36mg |
Market Status | Prescription |
Company | Janssen Pharms |
10 of 16 | |
---|---|
Drug Name | Metadate cd |
PubMed Health | Methylphenidate |
Drug Classes | CNS Stimulant, Central Nervous System Agent |
Drug Label | METADATE CD is a central nervous system (CNS) stimulant. The extended-release capsules comprise both immediate-release (IR) and extended-release (ER) beads such that 30% of the dose is provided by the IR component and 70% of the dose is provided by t... |
Active Ingredient | Methylphenidate hydrochloride |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | 30mg; 50mg; 60mg; 10mg; 40mg; 20mg |
Market Status | Prescription |
Company | Ucb |
11 of 16 | |
---|---|
Drug Name | Metadate er |
PubMed Health | Methylphenidate (By mouth) |
Drug Classes | CNS Stimulant, Central Nervous System Agent |
Drug Label | METADATE ER Tablets (methylphenidate hydrochloride extended-release tablets, USP) are a mild central nervous system (CNS) stimulant. METADATE ER is available as 20 mg extended-release tablets for oral administration.Methylphenidate hydrochloride is m... |
Active Ingredient | Methylphenidate hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | 20mg |
Market Status | Prescription |
Company | Ucb |
12 of 16 | |
---|---|
Drug Name | Methylin er |
PubMed Health | Methylphenidate |
Drug Classes | CNS Stimulant, Central Nervous System Agent |
Drug Label | Methylphenidate hydrochloride is a mild central nervous system (CNS) stimulant, available for oral administration as tablets of 5 mg, 10 mg, and 20 mg and as extended-release tablets of 10 mg and 20 mg. Methylphenidate hydrochloride is methyl -phen... |
Active Ingredient | Methylphenidate hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | 10mg; 20mg |
Market Status | Prescription |
Company | Mallinckrodt |
13 of 16 | |
---|---|
Drug Name | Methylphenidate hydrochloride |
Drug Label | Methylphenidate hydrochloride is a mild central nervous system (CNS) stimulant, available for oral administration as tablets of 5 mg, 10 mg, and 20 mg and as extended-release tablets of 10 mg and 20 mg. Methylphenidate hydrochloride is methyl -phen... |
Active Ingredient | Methylphenidate hydrochloride |
Dosage Form | Tablet, extended release; Tablet; Capsule, extended release; Solution |
Route | oral; Oral |
Strength | 10mg/5ml; 18mg; 30mg; 27mg; 36mg; 5mg; 54mg; 50mg; 60mg; 10mg; 5mg/5ml; 40mg; 20mg |
Market Status | Tentative Approval; Prescription |
Company | Corepharma; Vintage Pharms; Actavis Labs Fl; Sun Pharm Inds; Barr Labs; Mallinckrodt; Watson Labs; Actavis S Atlantic; Teva Pharms; Caraco; Ucb; Kudco Ireland; Tris Pharma |
14 of 16 | |
---|---|
Drug Name | Quillivant xr |
Drug Label | QUILLIVANT XR is a powder that, after reconstitution with water, forms an extended-release oral suspension formulation of methylphenidate intended for once daily oral administration. QUILLIVANT XR contains approximately 20% immediate-release and 80%... |
Active Ingredient | Methylphenidate hydrochloride |
Dosage Form | For suspension, extended release |
Route | Oral |
Strength | 5mg/ml |
Market Status | Prescription |
Company | Nextwave Pharms |
15 of 16 | |
---|---|
Drug Name | Ritalin |
Drug Label | Ritalin hydrochloride, methylphenidate hydrochloride USP, is a mild central nervous system (CNS) stimulant, available as tablets of 5, 10, and 20 mg for oral administration; Ritalin-SR is available as sustained-release tablets of 20 mg for oral admin... |
Active Ingredient | Methylphenidate hydrochloride |
Dosage Form | Tablet |
Route | Oral |
Strength | 5mg; 10mg; 20mg |
Market Status | Prescription |
Company | Novartis |
16 of 16 | |
---|---|
Drug Name | Ritalin la |
Drug Label | Methylphenidate hydrochloride is a central nervous system (CNS) stimulant. Ritalin LA (methylphenidate hydrochloride) extended-release capsules is an extended-release formulation of methylphenidate with a bi-modal release profile. Ritalin LA uses t... |
Active Ingredient | Methylphenidate hydrochloride |
Dosage Form | Capsule, extended release |
Route | Oral |
Strength | 30mg; 10mg; 40mg; 20mg |
Market Status | Prescription |
Company | Novartis |
Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Central Nervous System Stimulants
A loosely defined group of drugs that tend to increase behavioral alertness, agitation, or excitation. They work by a variety of mechanisms, but usually not by direct excitation of neurons. The many drugs that have such actions as side effects to their main therapeutic use are not included here. (See all compounds classified as Central Nervous System Stimulants.)
Dopamine Uptake Inhibitors
Drugs that block the transport of DOPAMINE into axon terminals or into storage vesicles within terminals. Most of the ADRENERGIC UPTAKE INHIBITORS also inhibit dopamine uptake. (See all compounds classified as Dopamine Uptake Inhibitors.)
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 10137
Submission : 1993-03-05
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-01-31
Pay. Date : 2013-01-07
DMF Number : 19547
Submission : 2006-06-26
Status : Active
Type : II
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
GDUFA
DMF Review : Complete
Rev. Date : 2014-07-07
Pay. Date : 2013-07-19
DMF Number : 27208
Submission : 2013-07-12
Status : Active
Type : II
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
GDUFA
DMF Review : Complete
Rev. Date : 2013-03-27
Pay. Date : 2012-11-23
DMF Number : 22244
Submission : 2008-12-19
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2016-09-19
Pay. Date : 2015-09-15
DMF Number : 29411
Submission : 2016-05-27
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15485
Submission : 2001-06-20
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2012-11-04
Pay. Date : 2012-11-16
DMF Number : 16331
Submission : 2002-12-20
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2013-02-08
Pay. Date : 2012-11-27
DMF Number : 12769
Submission : 1997-11-25
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 4599
Submission : 1982-06-16
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 12989
Submission : 1998-05-15
Status : Inactive
Type : II
Certificate Number : R1-CEP 2009-078 - Rev 00
Status : Valid
Issue Date : 2015-01-27
Type : Chemical
Substance Number : 2235
Certificate Number : CEP 2017-119 - Rev 01
Status : Valid
Issue Date : 2024-10-14
Type : Chemical
Substance Number : 2235
SCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.
SCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.
Certificate Number : R1-CEP 2012-168 - Rev 01
Status : Valid
Issue Date : 2022-09-09
Type : Chemical
Substance Number : 2235
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Certificate Number : CEP 2017-181 - Rev 02
Status : Valid
Issue Date : 2024-12-05
Type : Chemical
Substance Number : 2235
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
Certificate Number : CEP 2018-030 - Rev 04
Status : Valid
Issue Date : 2024-09-26
Type : Chemical
Substance Number : 2235
Certificate Number : R1-CEP 2009-254 - Rev 00
Status : Withdrawn by Holder
Issue Date : 2015-11-25
Type : Chemical
Substance Number : 2235
Certificate Number : R1-CEP 2009-094 - Rev 00
Status : Valid
Issue Date : 2015-08-03
Type : Chemical
Substance Number : 2235
Certificate Number : R1-CEP 2009-140 - Rev 01
Status : Valid
Issue Date : 2018-02-06
Type : Chemical
Substance Number : 2235
Certificate Number : R1-CEP 2016-073 - Rev 00
Status : Valid
Issue Date : 2022-03-08
Type : Chemical
Substance Number : 2235
Certificate Number : R1-CEP 2011-378 - Rev 01
Status : Valid
Issue Date : 2018-10-19
Type : Chemical
Substance Number : 2235
Registration Number : 302MF10009
Registrant's Address : 10 Wheatfield Road, Edinburgh EH11 2QA, United Kingdom
Initial Date of Registration : 2020-01-17
Latest Date of Registration : 2020-01-17
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
Methylphenidate Hydrochloride EP/USP
Date of Issue : 2022-08-25
Valid Till : 2025-07-02
Written Confirmation Number : WC-0195
Address of the Firm : Plot No. 3102/B, GIDC, Industrial Estate, Ankleshwar-393 002, Bharuch, Gujarat I...
Date of Issue : 2022-06-08
Valid Till : 2025-07-21
Written Confirmation Number : WC-0045nA2
Address of the Firm : Plot No. E-7, 8, 9 MIDC, Industrial Area, Chikalthana, Aurangabad-431006
Methyl phenidate Hydrochloride (BP/USP/ Ph.Eur)
Date of Issue : 2022-06-08
Valid Till : 2025-07-02
Written Confirmation Number : WC-0091
Address of the Firm : Sejavta, Ratlam, Madhya Pradesh
Biperiden Hydrochloride (Ph. Eur./USP)
Date of Issue : 2019-08-13
Valid Till : 2022-08-12
Written Confirmation Number : WC-0228
Address of the Firm : Sy No.505 Padmati Somaram Road Bibinagar Village and Mandal Nalgonda Dist AP
Biperiden hydrochloride Ph.Eur.USP
Date of Issue : 2018-10-01
Valid Till : 2021-10-01
Written Confirmation Number : WC-288
Address of the Firm : Sy.No.505 Padmati Somaram Road, Bldinagar Village and Mandal Nalgonda District T...
Methylphenidate Hydrochloride USP/EP
Date of Issue : 2022-08-08
Valid Till : 2025-07-14
Written Confirmation Number : WC-0168
Address of the Firm : Plot No. 24/2, & 25, Phase -IV, GIDC, Industrial Zone, At & Post - Panoli, Dist....
About the Company : Veranova is a global leader in the development and manufacturing of specialist and complex APIs for pharma and biotech customers. We have over 50 years of experience navigating the...
SCI Pharmtech offers high-quality, cost-effective APIs, advanced intermediates, & custom products with global expertise and precision.
About the Company : SCI Pharmtech Inc. offers APIs, advanced intermediates, and custom products, focusing on quick development and cost-effective production. Our research labs, pilot plants, and produ...
Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
About the Company : Cohance Lifesciences is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialzation. With our...
Malladi is a leader in Ephedrine, Pseudoephedrine Salts & Phenylephrine HCl // USFDA, EDQM, ANSM, KFDA, and TGA inspected.
About the Company : Malladi Drugs & Pharmaceuticals Ltd was founded in 1980 by microbiologist Mr. M L N Sastry. Within a few years, Malladi established itself as a leader in manufacturing ephedrine an...
About the Company : HRV Global is a leading global manufacturer, seller & exporter of a wide range of APIs, advanced intermediates, pellets, food grade chemicals, food additives & food ingredients. It...
Noramco is a partner to the pharmaceutical industry for controlled substance development & manufacturing.
About the Company : Founded in 1979, Noramco specializes in the development and manufacturing of APIs for both opioid and non-opioid products. With expertise in controlled substance development and ma...
About the Company : Back in the year 1973, a team of individuals came up with such an idea – The idea called Alkem. Looking back at our 5 decades, illustrious journey, that one small idea has Not on...
About the Company : Centaur accepts change as a constant, and continuously innovates to remain significant. Centaur has built knowledge sharing relationships with the pharmaceutical majors in areas of...
About the Company : Harman Finochem Limited is a leading India-based Pharmaceutical Company which specializes in the manufacture and export of more than 45 Active Pharmaceutical Ingredients (APls) of ...
About the Company : Ipca Laboratories, headquartered in Mumbai, India, is a prominent pharmaceutical enterprise established in 1949. Over the years, Ipca has emerged as a leading player in India's pha...
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Dr. Reddy’s Methylphenidate Hydrochloride Extended-Release Tablets, USP are available in strengths of 18 mg, 27 mg, 36 mg, and 54 mg tablets in bottle count sizes of 100.
Lead Product(s): Methylphenidate Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Methylphenidate Hydrochloride-Generic
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 09, 2020
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Dr. Reddy’s Methylphenidate Hydrochloride Extended-Release Tablets, USP are available in strengths of 18 mg, 27 mg, 36 mg, and 54 mg tablets in bottle count sizes of 100.
Product Name : Methylphenidate Hydrochloride-Generic
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 09, 2020
Details:
Quillivant (methylphenidate HCl) is a dopamine/norepinephrine reuptake inhibitor, which is indicated for the treatment of attention deficit hyperactivity disorder in patients aged 6 to 65 years.
Lead Product(s): Methylphenidate Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Quillivant XR
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 19, 2024
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Tris Pharma Expands Global ADHD Drug Availability with New Approvals
Details : Quillivant (methylphenidate HCl) is a dopamine/norepinephrine reuptake inhibitor, which is indicated for the treatment of attention deficit hyperactivity disorder in patients aged 6 to 65 years.
Product Name : Quillivant XR
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 19, 2024
Details:
Collegium will acquire Ironshore, which will help to expand into neurology, which includes JORNAY PM (methylphenidate HCl). It is indicated for the treatment of ADHD in patients 6 years and older.
Lead Product(s): Methylphenidate Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Jornay PM
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Collegium Pharmaceutical
Deal Size: $550.0 million Upfront Cash: $525.0 million
Deal Type: Acquisition July 29, 2024
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Collegium Pharmaceutical
Deal Size : $550.0 million
Deal Type : Acquisition
Collegium to Acquire Ironshore Therapeutics, Expanding into Neurology
Details : Collegium will acquire Ironshore, which will help to expand into neurology, which includes JORNAY PM (methylphenidate HCl). It is indicated for the treatment of ADHD in patients 6 years and older.
Product Name : Jornay PM
Product Type : Other Small Molecule
Upfront Cash : $525.0 million
July 29, 2024
Details:
Collegium will acquire Ironshore, which will help to expand into neurology, which includes JORNAY PM (methylphenidate HCl). It is indicated for the treatment of ADHD in patients 6 years and older.
Lead Product(s): Methylphenidate Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Jornay PM
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Collegium Pharmaceutical
Deal Size: $525.0 million Upfront Cash: $525.0 million
Deal Type: Acquisition April 09, 2024
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Collegium Pharmaceutical
Deal Size : $525.0 million
Deal Type : Acquisition
Collegium Completes Acquisition of Ironshore Therapeutics
Details : Collegium will acquire Ironshore, which will help to expand into neurology, which includes JORNAY PM (methylphenidate HCl). It is indicated for the treatment of ADHD in patients 6 years and older.
Product Name : Jornay PM
Product Type : Other Small Molecule
Upfront Cash : $525.0 million
April 09, 2024
Details:
Relexxii (methylphenidate HCl) is a dopamine/norepinephrine reuptake inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of attention deficit hyperactivity disorder in patients aged 6 to 65 years.
Lead Product(s): Methylphenidate Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Relexxii
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 19, 2023
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Alora Pharmaceuticals, LLC Announces the Availability of Once-Daily Relexxii® for the Treatment o...
Details : Relexxii (methylphenidate HCl) is a dopamine/norepinephrine reuptake inhibitor, small molecule drug candidate, which is currently being evaluated for the treatment of attention deficit hyperactivity disorder in patients aged 6 to 65 years.
Product Name : Relexxii
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 19, 2023
Details:
Quillivant ER (methylphenidate) Oral Suspension and Chewable Tablet R is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.
Lead Product(s): Methylphenidate Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Quillivant XR
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 25, 2023
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Quillivant ER (methylphenidate) Oral Suspension and Chewable Tablet R is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder.
Product Name : Quillivant XR
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 25, 2023
Details:
RELEXXII® (methylphenidate hydrochloride extended-release tablets) is an oral medication indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults up to the age of 65 and pediatric patients 6 years of age and older.
Lead Product(s): Methylphenidate Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Relexxii
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Osmotica Pharmaceuticals
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 07, 2022
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Osmotica Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RELEXXII® (methylphenidate hydrochloride extended-release tablets) is an oral medication indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults up to the age of 65 and pediatric patients 6 years of age and older.
Product Name : Relexxii
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 07, 2022
Details:
QuilliChew ER (methylphenidate hydrochloride) is a central nervous system (CNS) stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in people 6 years and older.
Lead Product(s): Methylphenidate Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Quillivant XR
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Teva Pharmaceutical Industries
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 18, 2022
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Tris Pharma Announces US District Court Upholds Validity of QuilliChew ER® Patents; Rules Teva In...
Details : QuilliChew ER (methylphenidate hydrochloride) is a central nervous system (CNS) stimulant prescription medicine used for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in people 6 years and older.
Product Name : Quillivant XR
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 18, 2022
Details:
Ritalin LA is indicated for the treatment of attention deficit hyperactivity disorder. The product is an extended-release formulation of methylphenidate hydrochloride with a bi-modal release profile using the proprietary SODAS® technology.
Lead Product(s): Methylphenidate Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Ritalin LA
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: InfectoPharm Drugs and Consilium
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 05, 2022
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : InfectoPharm Drugs and Consilium
Deal Size : Undisclosed
Deal Type : Agreement
Details : Ritalin LA is indicated for the treatment of attention deficit hyperactivity disorder. The product is an extended-release formulation of methylphenidate hydrochloride with a bi-modal release profile using the proprietary SODAS® technology.
Product Name : Ritalin LA
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 05, 2022
Details:
Ritalin LA is indicated for the treatment of attention deficit hyperactivity disorder. The product is an extended-release formulation of methylphenidate hydrochloride with a bi-modal release profile using the SODAS (Spheroidal Oral Drug Absorption System) technology.
Lead Product(s): Methylphenidate Hydrochloride
Therapeutic Area: Psychiatry/Psychology Brand Name: Ritalin LA
Study Phase: Approved FDFProduct Type: Other Small Molecule
Sponsor: Societal CDMO
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 05, 2022
Lead Product(s) : Methylphenidate Hydrochloride
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Partner/Sponsor/Collaborator : Societal CDMO
Deal Size : Undisclosed
Deal Type : Agreement
Details : Ritalin LA is indicated for the treatment of attention deficit hyperactivity disorder. The product is an extended-release formulation of methylphenidate hydrochloride with a bi-modal release profile using the SODAS (Spheroidal Oral Drug Absorption System...
Product Name : Ritalin LA
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
May 05, 2022
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB1
Brand Name : METHYLPHENIDATE HYDROCHLORIDE
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 20MG
Approval Date : 2011-12-01
Application Number : 78458
RX/OTC/DISCN : RX
RLD : No
TE Code : AB1
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB1
Brand Name : METHYLPHENIDATE HYDROCHLORIDE
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 30MG
Approval Date : 2011-12-01
Application Number : 78458
RX/OTC/DISCN : RX
RLD : No
TE Code : AB1
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB1
Brand Name : METHYLPHENIDATE HYDROCHLORIDE
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 40MG
Approval Date : 2011-12-01
Application Number : 78458
RX/OTC/DISCN : RX
RLD : No
TE Code : AB1
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB1
Brand Name : METHYLPHENIDATE HYDROCHLORIDE
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 60MG
Approval Date : 2016-06-23
Application Number : 78458
RX/OTC/DISCN : RX
RLD : No
TE Code : AB1
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB1
Brand Name : METHYLPHENIDATE HYDROCHLORIDE
Dosage Form : CAPSULE, EXTENDED RELEASE;ORAL
Dosage Strength : 10MG
Approval Date : 2018-02-26
Application Number : 200886
RX/OTC/DISCN : RX
RLD : No
TE Code : AB1
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
Brand Name : METHYLPHENIDATE HYDROCHLORIDE
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : 18MG
Approval Date : 2020-07-29
Application Number : 213473
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
Brand Name : METHYLPHENIDATE HYDROCHLORIDE
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : 27MG
Approval Date : 2020-07-29
Application Number : 213473
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
Brand Name : METHYLPHENIDATE HYDROCHLORIDE
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : 36MG
Approval Date : 2020-07-29
Application Number : 213473
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
RLD : No
TE Code : AB
Brand Name : METHYLPHENIDATE HYDROCHLORIDE
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : 54MG
Approval Date : 2020-07-29
Application Number : 213473
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
Brand Name : METHYLPHENIDATE HYDROCHLORIDE
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : 36MG
Approval Date : 2019-07-15
Application Number : 204659
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
Regulatory Info :
Registration Country : Norway
Brand Name : Methylphenidate Medical Valley
Dosage Form : Depot tablet
Dosage Strength : 18 mg
Packaging : Boks 30item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Switzerland
Brand Name : Methylphenidat-Mepha
Dosage Form : Depotabs
Dosage Strength : 54mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Switzerland
Brand Name : Ritalin LA
Dosage Form : Kaps
Dosage Strength : 20mg
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Switzerland
Regulatory Info :
Registration Country : Sweden
Brand Name : Concerta
Dosage Form : PROLONGED-RELEASE TABLET
Dosage Strength : 36 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Equasym Depot
Dosage Form : KAPSEL MED MODIFIERAD FRISÄTTNING, HÅRD
Dosage Strength : 10 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Medikinet
Dosage Form : KAPSEL MED MODIFIERAD FRISÄTTNING, HÅRD
Dosage Strength : 30 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Sweden
Brand Name : Ritalina
Dosage Form : KAPSEL MED MODIFIERAD FRISÄTTNING, HÅRD
Dosage Strength : 30 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Regulatory Info :
Registration Country : Norway
Brand Name : Methylphenidate Sandoz
Dosage Form : Depot tablet
Dosage Strength : 18 mg
Packaging : Bottle 30item
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Norway
Regulatory Info :
Registration Country : Sweden
Brand Name : Medikinet
Dosage Form : KAPSEL MED MODIFIERAD FRISÄTTNING, HÅRD
Dosage Strength : 40 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Regulatory Info :
Registration Country : Sweden
Brand Name : Medikinet
Dosage Form : KAPSEL MED MODIFIERAD FRISÄTTNING, HÅRD
Dosage Strength : 30 MG
Packaging :
Approval Date :
Application Number :
Regulatory Info :
Registration Country : Sweden
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
93
PharmaCompass offers a list of Methylphenidate Hydrochloride API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Methylphenidate Hydrochloride manufacturer or Methylphenidate Hydrochloride supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Methylphenidate Hydrochloride manufacturer or Methylphenidate Hydrochloride supplier.
PharmaCompass also assists you with knowing the Methylphenidate Hydrochloride API Price utilized in the formulation of products. Methylphenidate Hydrochloride API Price is not always fixed or binding as the Methylphenidate Hydrochloride Price is obtained through a variety of data sources. The Methylphenidate Hydrochloride Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Concerta manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Concerta, including repackagers and relabelers. The FDA regulates Concerta manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Concerta API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Concerta manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Concerta supplier is an individual or a company that provides Concerta active pharmaceutical ingredient (API) or Concerta finished formulations upon request. The Concerta suppliers may include Concerta API manufacturers, exporters, distributors and traders.
click here to find a list of Concerta suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Concerta DMF (Drug Master File) is a document detailing the whole manufacturing process of Concerta active pharmaceutical ingredient (API) in detail. Different forms of Concerta DMFs exist exist since differing nations have different regulations, such as Concerta USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Concerta DMF submitted to regulatory agencies in the US is known as a USDMF. Concerta USDMF includes data on Concerta's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Concerta USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Concerta suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Concerta Drug Master File in Japan (Concerta JDMF) empowers Concerta API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Concerta JDMF during the approval evaluation for pharmaceutical products. At the time of Concerta JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Concerta suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Concerta Drug Master File in Korea (Concerta KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Concerta. The MFDS reviews the Concerta KDMF as part of the drug registration process and uses the information provided in the Concerta KDMF to evaluate the safety and efficacy of the drug.
After submitting a Concerta KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Concerta API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Concerta suppliers with KDMF on PharmaCompass.
A Concerta CEP of the European Pharmacopoeia monograph is often referred to as a Concerta Certificate of Suitability (COS). The purpose of a Concerta CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Concerta EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Concerta to their clients by showing that a Concerta CEP has been issued for it. The manufacturer submits a Concerta CEP (COS) as part of the market authorization procedure, and it takes on the role of a Concerta CEP holder for the record. Additionally, the data presented in the Concerta CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Concerta DMF.
A Concerta CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Concerta CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Concerta suppliers with CEP (COS) on PharmaCompass.
A Concerta written confirmation (Concerta WC) is an official document issued by a regulatory agency to a Concerta manufacturer, verifying that the manufacturing facility of a Concerta active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Concerta APIs or Concerta finished pharmaceutical products to another nation, regulatory agencies frequently require a Concerta WC (written confirmation) as part of the regulatory process.
click here to find a list of Concerta suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Concerta as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Concerta API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Concerta as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Concerta and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Concerta NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Concerta suppliers with NDC on PharmaCompass.
Concerta Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Concerta GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Concerta GMP manufacturer or Concerta GMP API supplier for your needs.
A Concerta CoA (Certificate of Analysis) is a formal document that attests to Concerta's compliance with Concerta specifications and serves as a tool for batch-level quality control.
Concerta CoA mostly includes findings from lab analyses of a specific batch. For each Concerta CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Concerta may be tested according to a variety of international standards, such as European Pharmacopoeia (Concerta EP), Concerta JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Concerta USP).